Objective
The combination of ageing populations, sedative lifestyle and unhealthy diet results in increase in such diseases as diabetes. One of the outcomes of diabetes is the occurrence of very severe and deep leg wounds. As diabetes distorts the body’s normal tissue regeneration processes, it often results in necrosis and amputations, which are still everyday practice even in developed countries. Everfill Oy is a university spin-off that has developed Everfill®, a patented allogeneic bioengineered product that will revolutionize the care of wounds. Everfill® uses extracted human bioactive growth factors that trigger the patient’s body to regenerate damaged tissues. This results in faster and more thorough healing. As Everfill® contains only human material and triggers the patient to regenerate own tissue, it is a superior product for dressings and wound gels. It is safe and well tolerated and has no side effects. Everfill® will enable curing currently incurable tissue defects and wounds, achieve massive savings in health care, and improve the quality of life for millions of people. Our estimate of its global revenue potential is over €350 million per year.
So far €0.7 million were invested into the scientific research conducted at the University of Tampere and related to Everfill® product. In order to launch the product commercialization phase, we are looking for €5 million funding for 2019-21, of which half from venture capital investors within the ongoing round A and another half from the SME Instrument. This funding will be used for gaining EU and US regulatory classification for the product, building up business process proof of concept to produce the product for clinical trials, and conducting the first phase of clinical trials in EU. Initial sales revenues from experimental patient care using the first batch of product will be generated during the project.
Our SME-1 feasibility study will have IPR, legal, commercial and operational feasibility dimensions.
Fields of science (EuroSciVoc)
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
-
H2020-EU.2.3. - INDUSTRIAL LEADERSHIP - Innovation In SMEs
MAIN PROGRAMME
See all projects funded under this programme -
H2020-EU.3. - PRIORITY 'Societal challenges
See all projects funded under this programme -
H2020-EU.2.1. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies
See all projects funded under this programme
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
SME-1 - SME instrument phase 1
See all projects funded under this funding scheme
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
(opens in new window) H2020-EIC-SMEInst-2018-2020
See all projects funded under this callCoordinator
Net EU financial contribution. The sum of money that the participant receives, deducted by the EU contribution to its linked third party. It considers the distribution of the EU financial contribution between direct beneficiaries of the project and other types of participants, like third-party participants.
00120 HELSINKI
Finland
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.